BullFrog AI Lands Big Pharma Deal To Crack Depression Drug Targets

Benzinga01:20

The agreement covers applying the company’s proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer’s drug discovery and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623328665?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/30/AI-Transforms-Healthcare_0.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-03-31 01:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623328665","market":"us","top_or_hot":-1,"title":"BullFrog AI Lands Big Pharma Deal To Crack Depression Drug Targets","media":"Benzinga","content":"<div>\n<p>The agreement covers applying the company’s proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer’s drug discovery and...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51547321/bullfrog-ai-lands-big-pharma-deal-to-crack-depression-drug-targets\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BullFrog AI Lands Big Pharma Deal To Crack Depression Drug Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBullFrog AI Lands Big Pharma Deal To Crack Depression Drug Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 01:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51547321/bullfrog-ai-lands-big-pharma-deal-to-crack-depression-drug-targets><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The agreement covers applying the company’s proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer’s drug discovery and...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51547321/bullfrog-ai-lands-big-pharma-deal-to-crack-depression-drug-targets\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIYY","symbol_name":"YIELDMAX AI OPTION INCOME STRATEGY ETF","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51547321/bullfrog-ai-lands-big-pharma-deal-to-crack-depression-drug-targets","article_id":"2623328665","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/30/AI-Transforms-Healthcare_0.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51547321/bullfrog-ai-lands-big-pharma-deal-to-crack-depression-drug-targets","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623328665","pubTimestamp":1774891200,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"The agreement covers applying the company’s proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder , accelerating the Customer’s drug discovery and clinical development program.The agreement also provides exclusive access to a target candidate.Stellar Market Research valued the MDD market at more than $8 billion in 2025 and expects it to grow at an average annual rate of nearly 5%, reaching in excess of $11 billion by 2032.The agreement is expected to enhance Bullfrog AI’s capabilities in advancing medicines through its analytical AI/ML platform, bfLEAP.The partnership is a significant step forward for the company, potentially leading to new therapeutic developments in a critical area of healthcare.Last week, BullFrog AI introduced bfARENAS, a scenario-based decision engine.The engine aims at improving pharmaceutical portfolio strategy and clinical trial design, as the company looks to address inefficiencies in drug development driven by ","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","AI":"C3.ai, Inc.","BK4587":"ChatGPT概念","BK4551":"寇图资本持仓","AIPO":"Defiance AI and Power Infrastructure ETF","BK4588":"碎股","AGIX":"通用人工智能 ETF-AGIX","BK4528":"SaaS概念","BK4585":"ETF&股票定投概念","BK4023":"应用软件","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4543":"AI"},"translate_title":"BullFrog AI与大型制药公司达成协议以突破抑郁症药物目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIX":1.5,"CHAT":1.5,"AIPO":1.5,"AIYY":0.6,"AI":0.7},"content_text":"The agreement covers applying the company’s proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer’s drug discovery and clinical development program.\nThe agreement also provides exclusive access to a target candidate.\nStellar Market Research valued the MDD market at more than $8 billion in 2025 and expects it to grow at an average annual rate of nearly 5%, reaching in excess of $11 billion by 2032.\nThe agreement is expected to enhance Bullfrog AI’s capabilities in advancing medicines through its analytical AI/ML platform, bfLEAP.\nThe partnership is a significant step forward for the company, potentially leading to new therapeutic developments in a critical area of healthcare.\nLast week, BullFrog AI introduced bfARENAS, a scenario-based decision engine.\nThe engine aims at improving pharmaceutical portfolio strategy and clinical trial design, as the company looks to address inefficiencies in drug development driven by high uncertainty and failure rates.\nThe company said that the new platform helps biotech and pharmaceutical organizations navigate complex R&D environments, where long timelines, limited capital, and high failure rates remain persistent challenges.\nVin Singh, founder and CEO of BullFrog AI, said on Wednesday that many companies still struggle to convert growing volumes of data into consistent and transparent decision-making frameworks. He noted that this often leads to inefficient capital allocation across development programs.\nBFRG Price Action: Bullfrog AI shares were up 172.48% at $1.38 at the time of publication on Monday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623328665","isCrawlerRequest":true}